Reviewing Nymox Pharmaceutical (NYMX) and Trinity Biotech (TRIB)

Share on StockTwits

Nymox Pharmaceutical (NASDAQ:NYMX) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Insider and Institutional Ownership

7.4% of Nymox Pharmaceutical shares are held by institutional investors. Comparatively, 57.7% of Trinity Biotech shares are held by institutional investors. 54.0% of Nymox Pharmaceutical shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Nymox Pharmaceutical and Trinity Biotech, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nymox Pharmaceutical 0 0 0 0 N/A
Trinity Biotech 0 0 0 0 N/A

Risk and Volatility

Nymox Pharmaceutical has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares Nymox Pharmaceutical and Trinity Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nymox Pharmaceutical -2,909.61% -863.35% -378.13%
Trinity Biotech -42.24% 3.74% 1.30%

Valuation and Earnings

This table compares Nymox Pharmaceutical and Trinity Biotech’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nymox Pharmaceutical $220,000.00 512.27 -$13.42 million N/A N/A
Trinity Biotech $99.14 million 0.81 -$40.27 million N/A N/A

Nymox Pharmaceutical has higher earnings, but lower revenue than Trinity Biotech.

Summary

Trinity Biotech beats Nymox Pharmaceutical on 5 of the 9 factors compared between the two stocks.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply